StockData
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. (EWTX) stock

EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$39.91−1.27 (-3.07%)

Close on Nov 20, 2026Market cap $4.33BP/E –Yield –

Edgewise Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Edgewise Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$158.83M. For fiscal 2025 it was -$144.07M. The highest annual figure on record is -$14.84M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$144.07M–
FY2024Dec 31, 2024-$110.34M–
FY2023Dec 31, 2023-$97.69M–
FY2022Dec 31, 2022-$58.18M–
FY2021Dec 31, 2021-$34.18M–
FY2020Dec 31, 2020-$14.84M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$42.50M–
Q1 FY2026Mar 31, 2026-$42.80M–
Q4 FY2025Dec 31, 2025-$38.67M–
Q3 FY2025Sep 30, 2025-$34.87M–
Q2 FY2025Jun 30, 2025-$32.63M–
Q1 FY2025Mar 31, 2025-$37.91M–
Q4 FY2024Dec 31, 2024-$27.23M–
Q3 FY2024Sep 30, 2024-$27.89M–
Q2 FY2024Jun 30, 2024-$26.32M–
Q1 FY2024Mar 31, 2024-$28.90M–
Q4 FY2023Dec 31, 2023-$26.99M–
Q3 FY2023Sep 30, 2023-$22.52M–
Q2 FY2023Jun 30, 2023-$20.99M–
Q1 FY2023Mar 31, 2023-$27.19M–
Q4 FY2022Dec 31, 2022-$15.15M–
Q3 FY2022Sep 30, 2022-$13.29M–
Q2 FY2022Jun 30, 2022-$16.80M–
Q1 FY2022Mar 31, 2022-$12.94M–
Q4 FY2021Dec 31, 2021-$9.50M–
Q3 FY2021Sep 30, 2021-$8.71M–
Q2 FY2021Jun 30, 2021-$9.85M–
Q1 FY2021Mar 31, 2021-$6.12M–
Q4 FY2020Dec 31, 2020-$4.64M–
Q3 FY2020Sep 30, 2020-$3.28M–
Q2 FY2020Jun 30, 2020-$4.17M–
Q1 FY2020Mar 31, 2020-$2.75M–

More Edgewise Therapeutics figures

See a number that looks wrong?